SCHEDULE: Jorey Chernett Boosts Stake in Oncology Institute to 10.2%

Jorey Chernett has reported beneficial ownership of 10.2% of Oncology Institute, Inc.'s common stock as of March 13, 2026.

Summary

• Jorey Chernett beneficially owns 10,115,944 shares of Oncology Institute, Inc. common stock.
• This represents 10.2% of the outstanding shares, based on 98,839,144 shares outstanding as of March 5, 2026.
• The shares were not acquired for the purpose of changing or influencing control of the issuer, except for activities related to a nomination under Rule 240.14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial individual stake suggests strong conviction in Oncology Institute's value proposition without immediate intent to disrupt corporate control.

Positives

• A significant individual investor, Jorey Chernett, holds a substantial 10.2% stake in Oncology Institute, Inc., indicating confidence in the company.
• The filing explicitly states the shares were not acquired for the purpose of changing or influencing control, which may suggest a passive investment intent.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a significant stake by an individual investor in a healthcare company like Oncology Institute can signal a belief in the long-term prospects of the sector, particularly in specialized areas like oncology, which often involve high R&D costs but also high potential returns. This type of disclosure can attract attention from other investors looking for conviction plays in the healthcare space.

Comparison to Industry Standards

• A 10.2% beneficial ownership stake by an individual is a substantial position, often exceeding the average individual investor's holdings in publicly traded companies.
• Such a significant stake by an individual like Jorey Chernett could be viewed similarly to a large institutional investment, which often signals a vote of confidence in the company's strategy or valuation, comparable to major fund managers taking significant positions in peer oncology firms.

Stakeholder Impact

• Shareholders: The disclosure of a significant individual stake might instill confidence among existing shareholders and attract new investors, potentially influencing stock liquidity and valuation.
• Management: The presence of a large, non-activist shareholder could provide a degree of stability, allowing management to focus on long-term strategic goals without immediate pressure for control changes.

Next Steps

• Jorey Chernett will be required to file further amendments to Schedule 13G if their beneficial ownership percentage changes by more than 1% or if their investment intent changes.

Key Dates

Recommendation

While a significant individual stake indicates confidence, this filing is purely an ownership disclosure and does not provide operational or financial performance data to warrant a "buy" or "sell" recommendation. It suggests a "hold" as it confirms a substantial investor's position without offering new fundamental insights into the company's business performance.

Keywords

Oncology Institute, Jorey Chernett, Schedule 13G, beneficial ownership, common stock, institutional investor, healthcare, oncology